{"id":11243,"date":"2024-03-27T15:23:43","date_gmt":"2024-03-27T15:23:43","guid":{"rendered":"https:\/\/news.talkwithrattan.com\/index.php\/2024\/03\/27\/dr-reddys-to-exclusively-distribute-sanofis-vaccine-portfolio-in-india-times-of-india\/"},"modified":"2024-03-27T15:23:43","modified_gmt":"2024-03-27T15:23:43","slug":"dr-reddys-to-exclusively-distribute-sanofis-vaccine-portfolio-in-india-times-of-india","status":"publish","type":"post","link":"https:\/\/news.talkwithrattan.com\/index.php\/2024\/03\/27\/dr-reddys-to-exclusively-distribute-sanofis-vaccine-portfolio-in-india-times-of-india\/","title":{"rendered":"Dr Reddy’s to exclusively distribute Sanofi’s vaccine portfolio in India – Times of India"},"content":{"rendered":"
\"Dr<\/div>\n
HYDERABAD: Dr Reddy\u2019s Laboratories on Wednesday informed the bourses has entered into an exclusive partnership with Sanofi<\/a> Healthcare India Pvt Ltd for the distribution of the latter\u2019s vaccine portfolio in the Indian market.
As part of the agreement, while Dr Reddy\u2019s will have exclusive rights to promote and distribute Sanofi\u2019s paediatric and adult vaccine brands in India, Sanofi will continue to own, manufacture, and import these brands to the country.
These include paediatric and adult vaccine brands such as Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U. These brands rang up combined sales of around Rs 426 crore (approx. US$51 million), as per IQVIA MAT February 2024.
The Hyderabad-based pharma major said the partnership is part of Dr Reddy\u2019s efforts to emerge as the partner of choice in increasing access to novel, innovative and trusted drugs for patients in India.
The alliance will give it a strong portfolio and a major presence in the vaccine segment, propelling it to second position among vaccine players in the country.
Pointing out that the Sanofi portfolio will give the company\u2019s presence in the vaccine segment a strong boost, Dr Reddy\u2019s Labs CEO for branded markets (India and emerging markets) MV Ramana said the company will get an opportunity to leverage its strengths in promotion and distribution to considerably expand engagement with healthcare professionals and help widen access of Sanofi\u2019s well-established and trusted vaccine brands in India.
\u201cWe continue our efforts to become the partner of choice in bringing novel, innovative and trusted drugs to patients in India through strategic collaborations,\u201d he added.
Pointing out that the alliance with Dr Reddy\u2019s will help Sanofit expand its geographic reach in the Indian market, Preeti Futnani, general manager for vaccines in India at Sanofi, said though vaccine confidence has reached its highest in India in the last few years, still a lot remains to be done for the rest of the country\u2019s large unvaccinated population.<\/div>\n